We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 16, 2020

Early Dose-Intensity Reduction of Palbociclib Decreases PFS in Patients With HR+ Metastatic Breast Cancer

Breast Cancer Research and Treatment


Additional Info

Breast Cancer Research and Treatment
Impact of Early Dose Intensity Reduction of Palbociclib on Clinical Outcomes in Patients With Hormone-Receptor-Positive Metastatic Breast Cancer
Breast Cancer Res Treat 2020 Jul 15;[EPub Ahead of Print], B Moftakhar, M Lekkala, M Strawderman, TC Smith, P Meacham, B Fitzgerald, CI Falkson, A Dhakal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading